Agenus Inc. (NASDAQ:AGEN) Receives $10.50 Average Price Target from Analysts

Agenus Inc. (NASDAQ:AGEN) has received a consensus rating of “Hold” from the six research firms that are covering the firm, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $10.50.

Several brokerages have recently commented on AGEN. Baird R W lowered Agenus from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. Robert W. Baird downgraded shares of Agenus from an “outperform” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $8.00 in a report on Friday, July 19th. Jefferies Financial Group reiterated a “hold” rating and set a $7.00 price target (up from $3.00) on shares of Agenus in a research report on Friday, July 19th. B. Riley reduced their price objective on Agenus from $42.00 to $18.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Finally, StockNews.com lowered Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th.

Hedge Funds Weigh In On Agenus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AGEN. Point72 DIFC Ltd acquired a new stake in shares of Agenus in the 2nd quarter worth approximately $51,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Agenus in the second quarter worth approximately $106,000. BNP Paribas Financial Markets boosted its stake in Agenus by 81.3% during the 1st quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 84,477 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 9,422 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after acquiring an additional 123,058 shares during the period. 61.46% of the stock is owned by institutional investors.

Agenus Price Performance

Shares of AGEN stock opened at $4.20 on Friday. The firm has a fifty day moving average of $5.05 and a two-hundred day moving average of $8.98. The firm has a market cap of $90.60 million, a P/E ratio of -0.37 and a beta of 1.37. Agenus has a 1-year low of $4.18 and a 1-year high of $19.69.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The company had revenue of $23.51 million during the quarter, compared to analyst estimates of $64.73 million. During the same period last year, the business earned ($4.00) EPS. On average, sell-side analysts expect that Agenus will post -10.87 EPS for the current year.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.